Compare · AZN vs NUVL
AZN vs NUVL
Side-by-side comparison of AstraZeneca PLC (AZN) and Nuvalent Inc. (NUVL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and NUVL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 26.7x NUVL ($9.79B).
- Over the past year, AZN is down 10.3% and NUVL is up 50.5% - NUVL leads by 60.8 points.
- NUVL has been more active in the news (37 items in the past 4 weeks vs 12 for AZN).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- Nuvalent Inc.
- Price
- $168.85-0.24%
- $123.96+0.01%
- Market cap
- $261.92B
- $9.79B
- 1M return
- -5.56%
- +0.46%
- 1Y return
- -10.32%
- +50.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 12
- 37
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Nuvalent Inc.
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest NUVL
- Amendment: SEC Form SCHEDULE 13G/A filed by Nuvalent Inc.
- Director by Deputization Flynn James E returned $427,056 worth of Class A Common Stock - Restricted Stock Units to the company (3,444 units at $124.00) and returned $2,138,807,800 worth of shares to the company (17,248,450 units at $124.00) (SEC Form 4) to satisfy withholding tax
- Director Meyers Michael L. returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Balcom Alexandra returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Srivastava Sapna returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Oliger Christy J. returned 6,091 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Squarer Ron returned 6,281 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Medical Officer Turner Christopher Durant returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- Chief Development Officer Noci Darlene returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Officer Lane Benjamin returned 29,433 units of Class A Common Stock - Restricted Stock Units to the company, was granted 7,120 units of Class A Common Stock - Performance Stock Units and returned 7,120 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)